Efficacy And Safety Of Sorafenib Targeted Therapy For Metastatic Renal Cell Carcinoma

Objective:To evaluate the survival and quality of life of patients with metastatic renal carcinoma by sorafenib targeted therapy,and to evaluate the effectiveness and safety of sorafenib in the clinical application.Methods:We collected information about metastatic renal cell carcinoma(RCC)treated by sorafenib in our hospital in the past 10 years through outpatient review and telephone follow-up.A total of 47 patients were initially treated with sorafenib 400mg of toluene sulfonic acid 2 times a day for oral treatment.According to the change of the disease,the dosage to 600mg was increased to 2 times a day or 2 times a day for oral administration of 800mg.A new standard(RECIST)was used to evaluate the efficacy of the patients every 3 months.At the same time,the drug related adverse reactions were observed in the outpatient check-up and blood routine examination,liver and kidney function electrolyte,urine routine and so on.Results:A total of 47 patients were followed up,of which 1 patients were rechecked for 10 years after 10 years of operation.After 2 years of 2 years,sorafenib had undergone lobectomy.The pathological type of lung adenocarcinoma was shown after operation,and the pathological types were not consistent with the primary pathological type.1 cases were right renal clear cell carcinoma.6 years after the operation,the single metastasis of right lower lobe was found.4 years after sorafenib's oral treatment,the lobectomy was performed.The postoperative pathology was clear cell carcinoma.The postoperative patients interrupted their medicine by themselves.At present,no new metastasis was found.7 cases were lost,and the other 9 patients withdrew from the study because of diarrhea,blood pressure control instability and hand foot syndrome.In the 29 patients,there were 3 cases of partial remission(PR),10 cases of disease stabilization(SD),8 cases of disease progression(PD),8 cases of death,objective remission rate(ORR)10.34%(3/29),disease control rate(DCR)44.82%(13/29),median progression free survival(PFS)8.7(3?32)months,and median total survival period(OS)13.7(10.5?35)months;the main adverse reactions were hypertension,diarrhea,nausea and vomiting,hand foot syndrome,skin toxicity,hair loss,fatigue and so on,among which the adverse reactions reached level ? above:hypertension,diarrhea,and hand foot syndrome;of which 2 cases were interrupted for a period of time for abdominal diarrhoea and blood pressure control,respectively.Symptomatic support therapy was given,and after symptomatic remission,all patients returned to sorafenib standard dose therapy.Conclusion:Sorafenib was effective in the treatment of metastatic renal cancer,significantly prolonging the patient's life free life and improving the quality of life.After the disease progressed,the patients could still benefit by increasing the dose;most patients could tolerate drug related adverse reactions;the second line received Axitinib replacement for the late renal cancer patients who had failed in the Sorafenib treatment.Nepal targeted therapy can still benefit.